{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-073294","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.422421+00:00","generated_at":"2026-06-04T10:12:41.317530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cabaletta Bio reports Q4/FY2023 financials; first patient dosed with CABA-201 in myositis","bullets":["Cash, cash equivalents and short-term investments $241.2M as of Dec 31, 2023, with runway into 1H26.","R&D expenses $17.4M (Q4) and $55.4M (FY2023); G&A $5.7M (Q4) and $19.2M (FY2023).","First patient dosed in Phase 1/2 RESET-Myositis trial; no CRS or ICANS observed in first 21 days.","Initial clinical data from RESET-Myositis and RESET-SLE expected in 1H24; longer-term follow-up in 2H24.","FDA granted Rare Pediatric Disease designation for CABA-201 in juvenile dermatomyositis."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-073294","json":"https://secwatch.observer/filing/0001193125-24-073294.json","markdown":"https://secwatch.observer/filing/0001193125-24-073294.md","text":"https://secwatch.observer/filing/0001193125-24-073294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/0001193125-24-073294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/d717290d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:12:41.317530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31910e7f06f424c597ccd87e6249c6f71865d822","claim":"Cabaletta Bio, Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_excerpt":"Cabaletta Bio, Inc. (the “Company”) announced its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524073294/0001193125-24-073294-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}